MedPath

Sufentanil

Generic Name
Sufentanil
Brand Names
Dsuvia, Sufenta, Dzuveo
Drug Type
Small Molecule
Chemical Formula
C22H30N2O2S
CAS Number
56030-54-7
Unique Ingredient Identifier
AFE2YW0IIZ

Overview

Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as Dsuvia, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments . Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately . The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018 . This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural administration , .

Background

Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as Dsuvia, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments . Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately . The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018 . This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural administration , .

Indication

The indications for this drug are as follows:

Associated Conditions

  • Acute Pain
  • Severe Acute Pain

FDA Approved Products

Sufentanil Citrate
Manufacturer:Akorn
Route:INTRAVENOUS, EPIDURAL
Strength:50 ug in 1 mL
Approved: 2014/03/31
NDC:17478-050
Sufentanil Citrate
Manufacturer:Hospira, Inc.
Route:EPIDURAL, INTRAVENOUS
Strength:50 ug in 1 mL
Approved: 2023/07/17
NDC:0409-3382
Sufentanil Citrate
Manufacturer:West-Ward Pharmaceuticals Corp.
Route:EPIDURAL, INTRAVENOUS
Strength:0.05 mg in 1 mL
Approved: 2018/09/17
NDC:0641-6111
Sufentanil Citrate
Manufacturer:West-Ward Pharmaceuticals Corp.
Route:EPIDURAL, INTRAVENOUS
Strength:0.05 mg in 1 mL
Approved: 2018/09/17
NDC:0641-6112
Sufentanil Citrate
Manufacturer:West-Ward Pharmaceuticals Corp.
Route:EPIDURAL, INTRAVENOUS
Strength:0.05 mg in 1 mL
Approved: 2018/09/17
NDC:0641-6110

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath